183 related articles for article (PubMed ID: 25711717)
41. Intragastric pH and serum gastrin during administration of different doses of pantoprazole in healthy subjects.
Koop H; Kuly S; Flüg M; Eissele R; Mönnikes H; Rose K; Lühmann R; Schneider A; Fischer R; Arnold R
Eur J Gastroenterol Hepatol; 1996 Sep; 8(9):915-8. PubMed ID: 8889461
[TBL] [Abstract][Full Text] [Related]
42. Low-dose intravenous pantoprazole for optimal inhibition of gastric acid in Korean patients.
Oh JH; Choi MG; Dong MS; Park JM; Paik CN; Cho YK; Jeong JJ; Lee IS; Kim SW; Han SW; Choi KY; Chung IS
J Gastroenterol Hepatol; 2007 Sep; 22(9):1429-34. PubMed ID: 17645482
[TBL] [Abstract][Full Text] [Related]
43. Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole.
Goldstein JL; Miner PB; Schlesinger PK; Liu S; Silberg DG
Aliment Pharmacol Ther; 2006 Apr; 23(8):1189-96. PubMed ID: 16611280
[TBL] [Abstract][Full Text] [Related]
44. Can famotidine and omeprazole be combined on a once-daily basis?
Fändriks L; Lönroth H; Pettersson A; Vakil N
Scand J Gastroenterol; 2007 Jun; 42(6):689-94. PubMed ID: 17505990
[TBL] [Abstract][Full Text] [Related]
45. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Miner P; Katz PO; Chen Y; Sostek M
Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
[TBL] [Abstract][Full Text] [Related]
46. Comparison of p.o. or i.v. proton pump inhibitors on 72-h intragastric pH in bleeding peptic ulcer.
Javid G; Zargar SA; U-Saif R; Khan BA; Yatoo GN; Shah AH; Gulzar GM; Sodhi JS; Khan MA
J Gastroenterol Hepatol; 2009 Jul; 24(7):1236-43. PubMed ID: 19682194
[TBL] [Abstract][Full Text] [Related]
47. Suppression of gastric acid secretion by intravenous administration of famotidine in children.
Treem WR; Davis PM; Hyams JS
J Pediatr; 1991 May; 118(5):812-6. PubMed ID: 2019939
[TBL] [Abstract][Full Text] [Related]
48. The effect of rabeprazole alone or in combination with H2 receptor blocker on intragastric pH: a pilot study.
Törüner M; Bektaş M; Cetinkaya H; Soykan I; Ozden A
Turk J Gastroenterol; 2004 Dec; 15(4):225-8. PubMed ID: 16249975
[TBL] [Abstract][Full Text] [Related]
49. Prospective, randomized comparison of lansoprazole suspension, and intermittent intravenous famotidine on gastric pH and acid production in critically ill neurosurgical patients.
Brophy GM; Brackbill ML; Bidwell KL; Brophy DF
Neurocrit Care; 2010 Oct; 13(2):176-81. PubMed ID: 20596795
[TBL] [Abstract][Full Text] [Related]
50. Comparison of gastric pH with omeprazole magnesium 20.6 mg (Prilosec OTC) o.m. famotidine 10 mg (Pepcid AC) b.d. and famotidine 20 mg b.d. over 14 days of treatment.
Miner PB; Allgood LD; Grender JM
Aliment Pharmacol Ther; 2007 Jan; 25(1):103-9. PubMed ID: 17229225
[TBL] [Abstract][Full Text] [Related]
51. Famotidine versus pantoprazole for preventing bleeding in the upper gastrointestinal tract of critically ill patients receiving mechanical ventilation.
Ojiako K; Shingala H; Schorr C; Gerber DR
Am J Crit Care; 2008 Mar; 17(2):142-7. PubMed ID: 18310651
[TBL] [Abstract][Full Text] [Related]
52. A prospective, randomized, masked, placebo-controlled crossover study for the effect of 10 mg omeprazole capsules on gastric pH in healthy dogs.
Gaier A; Price J; Grubb L; Fitzgerald S; Tolbert MK
J Vet Intern Med; 2021 Mar; 35(2):887-891. PubMed ID: 33586200
[TBL] [Abstract][Full Text] [Related]
53. Clinical trial: gastric acid suppression in Hispanic adults with symptomatic gastro-oesophageal reflux disease - comparator study of esomeprazole, lansoprazole and pantoprazole.
Morgan D; Pandolfino J; Katz PO; Goldstein JL; Barker PN; Illueca M
Aliment Pharmacol Ther; 2010 Jul; 32(2):200-8. PubMed ID: 20456300
[TBL] [Abstract][Full Text] [Related]
54. Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status.
Sugimoto M; Furuta T; Shirai N; Ikuma M; Hishida A; Ishizaki T
Clin Pharmacol Ther; 2006 Nov; 80(5):539-48. PubMed ID: 17112810
[TBL] [Abstract][Full Text] [Related]
55. Pharmacodynamic effects of 3-day intravenous treatment with pantoprazole or ranitidine after 10 days of oral ranitidine.
Ley LM; Becker A; Lühmann R; Sander P; Lücker PW
Methods Find Exp Clin Pharmacol; 2005; 27(1):25-9. PubMed ID: 15834456
[TBL] [Abstract][Full Text] [Related]
56. Preventive effects of lansoprazole and famotidine on gastric mucosal injury induced by low-dose aspirin in Helicobacter pylori-negative healthy volunteers.
Nishino M; Sugimoto M; Kodaira C; Yamade M; Uotani T; Shirai N; Ikuma M; Tanaka T; Sugimura H; Hishida A; Furuta T
J Clin Pharmacol; 2011 Jul; 51(7):1079-86. PubMed ID: 20663999
[TBL] [Abstract][Full Text] [Related]
57. Use of automatic computerised pump to maintain constant intragastric pH.
Hannan A; Chesner I; Merki HS; Mann S; Walt RP
Gut; 1990 Nov; 31(11):1246-9. PubMed ID: 2253907
[TBL] [Abstract][Full Text] [Related]
58. Pharmacodynamics and dose-response relationship of famotidine: a double-blind randomized placebo-controlled trial.
Laskin OL; Patterson PM; Shingo S; Lasseter KC; Shamblen EC
J Clin Pharmacol; 1993 Jul; 33(7):636-9. PubMed ID: 8366188
[TBL] [Abstract][Full Text] [Related]
59. Optimizing the intragastric pH as a supportive therapy in upper GI bleeding.
Brunner G; Luna P; Hartmann M; Wurst W
Yale J Biol Med; 1996; 69(3):225-31. PubMed ID: 9165691
[TBL] [Abstract][Full Text] [Related]
60. Intermittent intravenous pantoprazole and continuous cimetidine infusion: effect on gastric pH control in critically ill patients at risk of developing stress-related mucosal disease.
Somberg L; Morris J; Fantus R; Graepel J; Field BG; Lynn R; Karlstadt R
J Trauma; 2008 May; 64(5):1202-10. PubMed ID: 18469642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
